Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC):a multicentre, open-label, randomised trial
| Title: | Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC):a multicentre, open-label, randomised trial |
|---|---|
| Authors: | Klaver, CEL; Wisselink, DD; Punt, CJ; Snaebjornsson, P; Crezee, J; Aalbers, AGJ; Brandt - Kerkhof, Alexandra; Bremers, AJ; Burger, JWA; Fabry, HFJ; Ferenschild, F; Festen, S; van Grevenstein, WMU; Hemmer, PH; de Hingh, I; Kok, NFM; Musters, GD; Schoonderwoerd, L; Tuynman, JB; Ven, AWH; van Westreenen, H L; Wiezer, MJ; Zimmerman, DDE; van Zweeden, AA; Dijkgraaf, MG; Tanis, Pieter J. |
| Source: | Klaver, CEL, Wisselink, DD, Punt, CJ, Snaebjornsson, P, Crezee, J, Aalbers, AGJ, Brandt - Kerkhof, A, Bremers, AJ, Burger, JWA, Fabry, HFJ, Ferenschild, F, Festen, S, van Grevenstein, WMU, Hemmer, PH, de Hingh, I, Kok, NFM, Musters, GD, Schoonderwoerd, L, Tuynman, JB, Ven, AWH, van Westreenen, H L, Wiezer, MJ, Zimmerman, DDE, van Zweeden, AA, Dijkgraaf, MG & Tanis, P J 2019, 'Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC) : a multicentre, open-label, randomised trial', Lancet Gastroenterology & Hepatology, vol. 4, no. 10, pp. 761-770. https://doi.org/10.1016/s2468-1253(19)30239-0 |
| Publication Year: | 2019 |
| Subject Terms: | /dk/atira/pure/keywords/researchprograms/AFL001000/EMCMM034711; name=EMC MM-03-47-11; /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being; name=SDG 3 - Good Health and Well-being |
| Description: | Background Nearly a quarter of patients with locally advanced (T4 stage) or perforated colon cancer are at risk of developing peritoneal metastases, often without curative treatment options. We aimed to determine the efficacy of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with locally advanced colon cancer. Methods This multicentre, open-label trial was done in nine hospitals that specialised in HIPEC in the Netherlands. Patients with clinical or pathological T4N0–2M0-stage tumours or perforated colon cancer were randomly assigned (1:1), with a web-based randomisation application, before resection of the primary tumour, to adjuvant HIPEC followed by routine adjuvant systemic chemotherapy (experimental group) or to adjuvant systemic chemotherapy alone (control group). Patients were stratified by tumour characteristic (T4 or perforation), age ( |
| Document Type: | article in journal/newspaper |
| Language: | English |
| ISSN: | 2468-1253 |
| Relation: | info:eu-repo/semantics/altIdentifier/pissn/2468-1253 |
| DOI: | 10.1016/s2468-1253(19)30239-0 |
| Availability: | https://pure.eur.nl/en/publications/ddb55f09-528f-4708-bbed-1fefe017c0c6; https://doi.org/10.1016/s2468-1253(19)30239-0; https://hdl.handle.net/1765/121062 |
| Rights: | info:eu-repo/semantics/closedAccess |
| Accession Number: | edsbas.DA7F2A65 |
| Database: | BASE |